You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR CLOBEX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CLOBEX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00400725 ↗ Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis Completed Galderma Phase 3 2006-09-01 The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly.
NCT00400725 ↗ Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis Completed Galderma R&D Phase 3 2006-09-01 The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly.
NCT00436540 ↗ A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam Completed Galderma Laboratories, L.P. Phase 4 2006-03-01 The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.
NCT00437216 ↗ Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis Completed Galderma Laboratories, L.P. 2006-02-01 Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.
NCT00437255 ↗ Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis Completed Galderma Laboratories, L.P. Phase 4 2006-08-01 Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
NCT00438399 ↗ Subject Preference for Scalp Psoriasis Treatment Completed Galderma Phase 3 2007-02-01 The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress. Topical agents remain the mainstay of treatment for scalp psoriasis. However, they are not always ideal because they might be inconvenient and messy to use, stain or damage hair. The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a short-contact therapy in order to improve the chances of it being effective and reduce the potential for traditional side-effects. The objective of this study is to compare subject's overall preference between Clobetasol propionate shampoo 0.05% and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis.
NCT00438399 ↗ Subject Preference for Scalp Psoriasis Treatment Completed Galderma R&D Phase 3 2007-02-01 The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress. Topical agents remain the mainstay of treatment for scalp psoriasis. However, they are not always ideal because they might be inconvenient and messy to use, stain or damage hair. The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a short-contact therapy in order to improve the chances of it being effective and reduce the potential for traditional side-effects. The objective of this study is to compare subject's overall preference between Clobetasol propionate shampoo 0.05% and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CLOBEX

Condition Name

Condition Name for CLOBEX
Intervention Trials
Plaque Psoriasis 4
Psoriasis 4
Scalp Psoriasis 2
Chronic Stable Plaque Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CLOBEX
Intervention Trials
Psoriasis 12
Erythema Multiforme 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CLOBEX

Trials by Country

Trials by Country for CLOBEX
Location Trials
United States 29
Canada 2
France 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CLOBEX
Location Trials
Texas 5
California 5
New York 3
Minnesota 3
Michigan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CLOBEX

Clinical Trial Phase

Clinical Trial Phase for CLOBEX
Clinical Trial Phase Trials
Phase 4 8
Phase 3 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CLOBEX
Clinical Trial Phase Trials
Completed 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CLOBEX

Sponsor Name

Sponsor Name for CLOBEX
Sponsor Trials
Galderma Laboratories, L.P. 7
Galderma 2
Galderma R&D 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CLOBEX
Sponsor Trials
Industry 16
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.